Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TY014 in Healthy and YFV-Challenged Volunteers
NCT03776786Phase 1Completed
- Sponsor
- Tysana Pte Ltd
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TY014 in yellow fever (14 arms), sponsored by Tysana Pte Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Event at 84 Days and Percentage Aviremia Post Treatment at 14 Days. Started Dec 2018; status: completed.
02
Drugs
TY014
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT03776786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776786.